Side effects of combined therapy of methylprednisolone and intravenous immunoglobulin in Guillain-Barré syndrome

European Neurology

Volumn 53, Issue 4, 2005, Pages 194-196

  Odaka, M ^a   Tatsumoto, M ^a   Hoshiyama, E ^a   Hirata, K ^a   Yuki, N ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Guillain Barr syndrome; Intravenous immunoglobulin; Methylprednisolone; Side effect

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE; STEROID; GAMMA GLUTAMYLTRANSFERASE; MICROSOMAL AMINOPEPTIDASE; NEUROPROTECTIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER DYSFUNCTION; MALAISE; MALE; NAUSEA; PRIORITY JOURNAL; RASH; SKIN TINGLING; THORAX PAIN; VOMITING; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; DRUG COMBINATION; LIVER DISEASE; MIDDLE AGED; TIME;

ADULT; AGED; ANTIGENS, CD13; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GUILLAIN-BARRE SYNDROME; HEADACHE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LIVER DISEASES; MALE; METHYLPREDNISOLONE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; TIME FACTORS;

EID: 24944488518     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086477     Document Type: Article

References (10)

1. van Koningsveld R, Schmitz PIM, van der Meché FGA, Visser LH, Meulstee J, van Doorn PA, for the Dutch GBS Study Group: Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004;363:192-196.
2. van Koningsveld R, van der Meché FG, Schmitz PI, van Doom PA: Combined therapy of intravenous immunoglobulin and methylprednisolone in patients with Guillain-Barré syndrome: the results of a multicentre double-blind placebo controlled randomised clinical trial. J Peripher Nerv Syst 2001;6:186-187.
3. Lederman HM, Roifman CM, Lavi S, Gelfand EW: Corticosteroids for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patients. Am J Med 1986;81:443-446.
4. Asbury AK, Cornblath DR: Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27:S21-S24.
5. Oomes PG, van der Meché FGA, Kleyweg RP, and the Dutch Guillain-Barré Study Group: Liver function disturbances in Guillain-Barré syndrome: a prospective longitudinal study in 100 patients. Neurology 1996;46:96-100.
6. Stangel M, Kiefer R, Pette M, Smolka MN, Marx P, Gold R: Side effects of intravenous immunoglobulins in neurological autoimmune disorders: a prospective study. J Neurol 2003;250:818-821.
7. Weissel M, Hauff W: Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000;10:521.
8. Casteels-van Daele M, Wijndaele L, Hanninck K, Gillis P: Intravenous immune globulin and acute aseptic meningitis. N Engl J Med 1990;323:614-615.
9. Sekul EA, Cupler EJ, Dalakas MC: Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-262.
10. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP: Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996;47:674-677.